Ulcerative Colitis Market is Anticipated to Witness a Promising CAGR of 7% During For 2017-2022
Market Highlights:
The global Ulcerative colitis market has been
evaluated as growing market and expected that the market will reach high growth
figures in the coming future. Ulcerative colitis is a type of inflammatory
bowel disease (IBD) that usually affects the lower section of body such as
sigmoid colon and the rectum. Belly pain or cramps, diarrhea and bleeding from
the rectum are some of the common symptoms of the diseases. According to CDC,
the worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000
persons per year. The reappearance of the disease’s symptoms is also high.
Blockbuster drugs losing patent protection and
growing the propensity for generic drugs are turning out to be restraints for
the market. The lack of curative therapy and personalized therapy and
medication are big opportunities for the market.
Major factors leading to the growth of the market
includes increasing prevalence of ulcerative colitis, higher preference for
symptomatic therapeutic, better treatment of inflammatory bowel diseases,
arrival of enhanced drugs and healthier investments in R&D programs.
Increasing patient pool with unmet needs, new drugs entering the market,
increasing global incidence & prevalence rate, and increasing investments
towards research in small molecules are some of the other factors leading the
market growth.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/2354
Key Players:
Key players profiled in the report are
·
Allergan
·
AbbVie
Inc
·
Takeda
Pharmaceutical Company Limited
·
Bayer AG
·
UCB S.A.
·
Perrigo
Company plc
·
Pfizer
Inc
·
Johnson
& Johnson Services
·
Ferring
B.V.
·
Janssen Biotech
·
Merck
Segmentation:
·
Global
Ulcerative Colitis Market is segmented on the basis of types and medication.
·
Based on
types, the market is segmented as ulcerative proctitis, proctosigmoiditis,
left-sided colitis, pancolitis or universal colitis, and fulminant colitis.
Ulcerative proctitis is expected to command the largest market share during the
forecast period.
·
Further
on the basis of medication the market is classified into 5-aminosalicylates,
steroids, purine analogs, immunomodulators, and biologics. Biologics are
expected to command the largest market. Steroids drugs are expected to grow at
the highest CAGR during the forecast period.
Regional
Analysis:
North America is expected to account for the
largest share of the global Ulcerative colitis Market in 2016, followed by
Europe, the region will continue to lead the pack during the forecast period.
In Asia-Pacific, China leads the market. Economic development and improvement
of healthcare facilities are propelling the growth of the market. The entry of
Simponi and Entyvio is likely to petrol the growth of the market. However,
Humira which lost its patent in 2016 and Remicade, which will lose its patent
in 2018 and will not have a positive impact on the market.
Access Full Report Details and TOC Exclusively @ https://www.marketresearchfuture.com/reports/ulcerative-colitis-market-2354
About Market Research Future:
At Market Research Future (MRFR), we
enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact
Akash Anand,
Market Research Future
Office No. 528,
Amanora Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com
Normal blood oxygen levels in humans are considered 95–100 percent. If the level is below 90 percent, it is considered low resulting in hypoxemia. Blood oxygen levels below 80 percent may compromise organ function, such as the brain and heart, and should be promptly addressed. check your Pulse Oximeter
ReplyDelete